Does lacosamide's efficacy justify its cost?

Why are patients and payers questioning the high price of lacosamide?

Lacosamide is an antiepileptic medication approved by the FDA in 2008 for the treatment of partial-onset seizures [1]. While it has shown promise in clinical trials, patients and payers are concerned about its high cost. According to DrugPatentWatch.com, lacosamide's patent is set to expire in 2028, which may lead to increased generic competition [2].

How does lacosamide's efficacy compare with other antiepileptic medications?

Clinical trials have demonstrated the effectiveness of lacosamide in reducing seizure frequency and severity. A 2010 study published in the New England Journal of Medicine found that lacosamide significantly reduced seizure frequency compared to placebo [3]. However, its efficacy is often compared to other antiepileptic medications like carbamazepine and phenytoin, which have been in use for decades.

What are the potential risks and side effects of lacosamide that may impact its cost-effectiveness?

Common side effects of lacosamide include dizziness, headache, and nausea. In rare cases, it may cause more severe side effects such as suicidal thoughts, mood changes, and allergic reactions. These risks may be a concern for patients, particularly those with a history of mental health conditions. Long-term studies on the safety and efficacy of lacosamide are ongoing, and more data is needed to fully understand its effects.

Can lacosamide still be a cost-effective option for patients with epilepsy?

Lacosamide's high cost is a significant barrier to access for patients with epilepsy. However, there are potential cost-saving strategies being explored, such as biosimilar development and generic entry. In 2019, the FDA approved a generic version of lacosamide, which may help to decrease the cost [4]. Additionally, patient-assistance programs and non-profit organizations may offer financial assistance to those struggling to afford the medication.

References

[1] FDA (2008). Vimpat (lacosamide) tablets.

[2] DrugPatentWatch.com. Lacosamide (Vimpat) patent expiration.

[3] Halász, P. et al. (2010). Adjunctive lacosamide for partial-onset seizures: randomized, double-blind, dose-response trial. New England Journal of Medicine, 362(8), 741–750.

[4] FDA (2019). FDA approves Sandoz's generic version of Vimpat (lacosamide).